Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Wynn Resorts, Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Wynn Resorts, Limited trades at $98.03 (market cap $10.00B). The key difference: Wynn Resorts, Limited is far larger — about 2.2× ACADIA Pharmaceuticals Inc.'s market cap, and Wynn Resorts, Limited pays a 1.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WYNN | |
|---|---|---|
Market Cap | $4.49B | $10.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $133.34 |
52-Week Low | $20.06 | $94.78 |
Enterprise Value | $3.69B | $20.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Wynn Resorts (WYNN) trades at $96.35, up 0.46% on the day, with a bearish technical signal and recent earnings misses. Revenue reached $7.14B in 2025, but net income declined to $327M, reflecting margin pressure. Analyst consensus remains strongly bullish with a $136.22 price target, though high debt and competitive headwinds persist. The company announced Q2 2026 earnings for August 4, 2026, with investor focus on Macau and Las Vegas performance.
The stock presents a contrarian opportunity given analyst optimism amid technical weakness. Upside hinges on earnings recovery and debt management, but risks include geopolitical tensions in Macau and sustained margin compression. Current valuation at P/E 27.47 may limit near-term gains without profit improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
